阿尔兹海默病β淀粉样蛋白形成和沉积的发病机制及中医药干预的可能途径  

Pathogenesis of Amyloid β Formation and Deposition in Alzheimer's Disease and Possible Intervention Strategies of Traditional Chinese Medicine

作　　者：闫蓉[1] 常翔[1] 杨从[1] 苏如玉[1] 侯雪芹[1] 张磊[1] 张春霞[1] 方淑环[1] 陈云波[1] 王奇[1] 

机构地区：[1]广州中医药大学临床药理研究所DME中心,广东广州510405

出　　处：《中药新药与临床药理》2013年第6期629-632,共4页Traditional Chinese Drug Research and Clinical Pharmacology

基　　金：广东省科技计划项目(2010A030100009);广东省重大科技专项(2012A080202017);教育部高等学校博士学科点专项科研基金(2011442110007);广东省高等学校科技创新项目(2012KJCX0032)

摘　　要：阿尔兹海默病(Alzheimer’s disease,AD)是以认知功能障碍和记忆损害为主要临床特征的神经退行性疾病,其病因复杂,并缺乏有效的诊断、治疗和预防手段。β淀粉样蛋白(Aβ)被认为是AD治疗的关键靶标。Aβ是AD形成和发展的关键因素,以Aβ为靶标可能是AD预防和治疗的有效策略。中药对减少Aβ生成和沉积、促进Aβ清除方面已取得了系列的研究成果。中医药治疗AD应创新研究思路,以Aβ为靶标,开展方药配伍、临床试验研究,从而提高中医药治疗AD的疗效。Alzheimer＇s disease（AD） is a progressive neurodegenerative disorder which is characterized bypathological dementia and memory damage in clinic.Due to its complex pathogenesis, there is no effective method for its diagnosis, prevention and treatment. Recently, amyloid β （Aβ）, the key factor of the formation and development of AD, is considered as the possible targeted path of effectively preventing and treating AD. Traditional Chinese medicine has been demonstrated to be effective in reducing Aβ formation and deposition and in promoting Aβ, indicating traditional Chinese medicine can be expected to treat AD more effectively through the research of Aβ-targeted Chinese herbal medicine compatibility and the clinical trial.

关 键 词：老年性痴呆 Β-淀粉样蛋白 中药 

分 类 号：R741.02[医药卫生—神经病学与精神病学] R285.5[医药卫生—临床医学]